rhTPO Ameliorates Radiation-Induced Long-Term Hematopoietic Stem Cell Injury in Mice
Molecules · 2023
DOI: 10.3390/molecules28041953 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Hao Luan und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, Anhui Medical University, Hefei 230032, China. Hauptthemen laut MEDLINE: Radiation Injuries, Thrombopoietin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Fund of China, National Major Science and Technology Projects of China, Scientific Research Project of PLA.
Abstract (Originalsprache)
Exposure to medium and high doses of ionizing radiation (IR) can induce long-term bone marrow (BM) suppression. We previously showed that recombinant human thrombopoietin (rhTPO) significantly promotes recovery from hematopoietic-acute radiation syndrome, but its effect on long-term BM suppression remains unknown. C57BL/6 mice were exposed to 6.5 Gy γ-rays of total body irradiation (TBI) at a dose-rate of 63.01 cGy per minute, and the mice were treated with rhTPO (100 μg; intramuscular injection) or vehicle at 2 h after TBI. All mice were killed one or two months after TBI for analysis of peripheral blood cell counts, long-term hematopoietic stem cell (HSC) frequency, and BM-derived clonogenic activity. The HSC self-renewal capacity was analyzed by BM transplantation. The levels of reactive oxygen species (ROS) production and ratios of γH2AX+ and p16, p53, and p21 mRNA in HSCs were measured by flow cytometry and real-time polymerase chain reaction, respectively. Treatment with rhTPO reduced long-term myelosuppression by improving long-term hematopoietic reconstitution (p < 0.05) after transplantation and resting state maintenance of HSCs (p < 0.05). Moreover, rhTPO treatment was associated with a sustained reduction in long-term ROS production, reduction of long-term DNA damage, diminished p53/p21 mRNA expression, and prevention of senescence after TBI. This study suggests rhTPO is an effective agent for treating IR-induced long-term BM injury because it regulates hematopoietic remodeling and HSC cycle disorder through the ROS/p53/p21/p16 pathway long term after IR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science, Anhui Medical University, Hefei 230032, China.
- Beijing Key Laboratory for Radiobiology, Department of Experimental Hematology and Biochemistry, Beijing Institute of Radiation Medicine, Beijing 100850, China.
- Graduate School, Jinzhou Medicine University, Jinzhou 121001, China.
Förderung
- National Natural Science Fund of China
- National Major Science and Technology Projects of China
- Scientific Research Project of PLA
Zitieren
APA
Luan, H., Yang, J., Wang, Y., Shen, X., Zhang, X., Qiao, Z., Xing, S., & Yu, Z. (2023). rhTPO Ameliorates Radiation-Induced Long-Term Hematopoietic Stem Cell Injury in Mice. Molecules. https://doi.org/10.3390/molecules28041953
Vancouver
Luan H, Yang J, Wang Y, Shen X, Zhang X, Qiao Z, et al. rhTPO Ameliorates Radiation-Induced Long-Term Hematopoietic Stem Cell Injury in Mice. Molecules. 2023. doi:10.3390/molecules28041953
BibTeX
@article{Luan2023,
author = {Luan, Hao and Yang, Jinkun and Wang, Yemei and Shen, Xing and Zhang, Xuewen and Qiao, Zizhi and Xing, Shuang and Yu, Zuyin},
title = {rhTPO Ameliorates Radiation-Induced Long-Term Hematopoietic Stem Cell Injury in Mice},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28041953}
}
EUVIMED